I-309/CCL1

Product Information
Primary Accession	P22362-1
Species	Human
Sequence	Ser23-Lys96
Purity	> 97% as analyzed by SDS-PAGE > 97% as analyzed by HPLC
Endotoxin Level	< 1 EU/ µg of protein by LAL method
Biological Activity	Fully biologically active when compared to standard. The biological activity determined by a chemotaxis bioassay using human T-lymphocytes is in a concentration range of 10.0-100.0 ng/ml.
Expression System	E. coli
Theoretical Molecular Weight	8.6 kDa
Formulation	Lyophilized from a 0.2 µm filtered solution in 20 mM PB, pH 7.4, 100 mM NaCl.
Reconstitution	It is recommended that this vial be briefly centrifuged prior to opening to bring the contents to the bottom. Reconstitute the lyophilized powder in sterile distilled water or aqueous buffer containing 0.1% BSA to a concentration of 0.1-1.0 mg/ml.
Storage & Stability	Upon receiving, this product remains stable for up to 6 months at -70°C or -20°C. Upon reconstitution, the product should be stable for up to 1 week at 4°C or up to 3 months at -20°C. Avoid repeated freeze-thaw cycles.

Additional Information
Target Background	Human I-309/CCL1 was initially identified by subtractive hybridization as a transcript that was present in a γ/δ T cell line but not in EBV-transformed B cells. Human CCL1 has been assumed to be a homologue of the mouse TCA3. While the two proteins share only approximately 42% amino acid sequence identity, both chemokines contain an extra pair of cysteine residues not found in most other chemokines. Human CCL1 and mouse TCA3 also share significant sequence homology in the 5’ flanking region of their genes.